Vascular Endothelial Growth Factor (VEGF) and Interleukine (IL)- 6 in serum and seroma after breast cancer surgery

Authors

  • Nahida Srabovic Faculty of pharmacy University of Tuzla Tuzla, B&H
  • Adaleta Softic
  • Samra Hasanbasic
  • Adi Rifatbegovic
  • Jasminka Mujanovic Mustedanagic
  • Aida Smajlovic
  • Esmeralda Dautovic
  • Zdeno Muminovic
  • Selma Hadziabdic
  • Admira Dervisevic
  • Zlata Mujagic

DOI:

https://doi.org/10.5457/ams.v45i1-2.434

Keywords:

breast cancer, VEGF, IL-6, surgery, wound healing

Abstract

Due to better understanding complex immune-inflammatory responses following surgical injury, the aim of present study was to investigate the changes of VEGF and IL-6 levels in serum and seroma of invasive breast cancer patients after surgery and their correlation with breast cancer tumour expression of VEGF Samples from 20 breast cancer patients and 15 benign breast disease patients were included in the study. Immunohistochemical staining was used for determining VEGF expression in tissue samples from tumour, stromal and normal breast. Measuring VEGF and IL-6 levels was conducted by ELISA. Differences in VEGF expression between tumour and stroma (p=0,007) and between tumour and normal breast tissue were significant (p=0,0001), as well as differences in VEGF expression between stromal and normal breast tissue (p=0,004). Serum level of VEGF was higher in patients with breast cancer then in patients with benign breast disease, before surgery (p=0,023).VEGF was significantly elevated postoperatively in serum (p=0,009) and seroma (p=0,0001) in patients with breast cancer. Level of IL-6 was elevated after surgery in serum (p=0,015) and seroma (p=0,0001) in patients with breast cancer, as well as in serum of patients with benign breast disease (p=0,018). Significant correlation was found between seroma levels of VEGF and IL-6 in breast cancer patients (p=0,009). The findings suggest involvement of VEGF and IL-6 in physiological changes after breast cancer surgery.

Downloads

Published

2018-02-02

Issue

Vol. 45 No. 1-2 (2016): 1-2

Section

Original papers

License

Copyright transfer

The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.